RenovoRx (RNXT) IAccess Alpha Virtual MicroCap Conference summary

Strategic vision and market approach

• Focus on localizing cancer therapy to improve patient outcomes and reduce systemic toxicity.

• Two-prong strategy: commercializing the FDA-cleared RenovoCath device and developing a drug-device combination platform for pancreatic cancer.

• Achieved $900,000 in revenue through Q3 2025 without a dedicated sales force; lean sales infrastructure now in place.

• U.S. market prioritized due to favorable regulatory and reimbursement environment; international expansion planned for the future.

• Targeting high-volume surgery centers for efficient market penetration with a small sales team.

Clinical and commercial progress

• RenovoCath device delivers chemotherapy locally, achieving 100x higher tumor concentration and 50% lower systemic toxicity.

• Outpatient procedure with minimal side effects and rapid patient recovery compared to systemic chemotherapy.

• Device cleared for broad chemotherapy delivery; initial focus on locally advanced pancreatic cancer, with potential for other hypovascular tumors.

• 14 centers approved to purchase, 5 active customers, and 24 additional centers requesting quotes.

• Phase III TIGeR-PaC trial nearing enrollment completion in 2026, with final data expected in 2027.

Financial outlook and growth drivers

• Device-alone U.S. market estimated at $400 million peak annual revenue.

• Each patient can generate $40,000–$80,000 in revenue; early sales are lumpy but show repeat usage.

• Margins currently at 80%, expected to improve with manufacturing scale and design tweaks.

• Over $10 million in cash at Q3 2025; runway extends into mid-2026 with current burn rate.

• Revenue growth expected to ramp in late 2026 as more centers onboard and sales cycle matures.